Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ela3.0
Elamipretide – Forschung
Überwiegend Mechanismus / Beobachtung
22 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Elamipretide sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2016–2026 mit einer typischen Studiengröße von 19 Teilnehmenden.
Basierend auf 22 Studien · 1 Meta-Analyse · 14 RCTs · 58 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Mitochondrial disease & myopathy
Überwiegend Mechanismus / Beobachtung13 Studien
Cardiac & reperfusion
Überwiegend Mechanismus / Beobachtung7 Studien
Energy & fatigueEin mitochondrial gerichtetes (Cardiolipin-bindendes) Peptid, das die subjektive Erschöpfung verbesserte und in einer offenen Studie ein Signal beim Barth-Syndrom zeigte; verfehlte die zulassungsrelevanten Endpunkte zu Myopathie und Infarktgröße. · Nicht belegt
Überwiegend Mechanismus / Beobachtung5 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien
Vision & eye health
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
15 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2022
201620212026
1RCT2020
Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH · J Cachexia Sarcopenia Muscle (2020)
Einfach gesagt: Furthermore, we offer a comprehensive outlook on the expansive prospects of SS-31's future development and application.
Du X, Zeng Q, Luo Y, He L, Zhao Y, Li N, Han C, Zhang G, Liu W. · Mitochondrion (2024)
Its notable attributes encompass the mitigation of oxidative stress, the suppression of inflammatory processes, the maintenance of mitochondrial dynamics, and the prevention of cellular apoptosis.
As such, SS-31 may emerge as a viable choice for the treatment of mitochondrial dysfunction-related ailments in the foreseeable future.
Furthermore, we offer a comprehensive outlook on the expansive prospects of SS-31's future development and application.
Einfach gesagt: A comprehensive understanding of mitochondrial redox processes during gestational diabetes offers unique potential for improving pregnancy outcomes and may contribute to reducing the intergenerational inheritance of metabolic diseases.
Burzynska-Pedziwiatr I, Wozniak LA, Bukowiecka-Matusiak M. · Free radical biology & medicine (2026)
This structure identifies placental mitochondria as potential therapeutic targets.
Preclinical studies on mitochondrial antioxidants (SS-31, MitoQ), uncoupling factors, and biogenesis-supporting substances have shown great potential in restoring mitochondrial integrity and reducing oxidative stress.
However, there is still no clinical confirmation of their effectiveness during pregnancy.
Einfach gesagt: Administration of MTP-131 was not associated with a significant reduction in the primary endpoint, infarct size by CK-MB AUC over 72 h, nor with improvement in prespecified MRI, angiographic, electrocardiographic, or clinical outcomes.
Gibson CM, Giugliano RP, Kloner RA, Bode C, Tendera M, Jánosi A, et al. · Eur Heart J (2016)
Multicentre, randomized, double-blind Phase 2a trial of IV MTP-131 (elamipretide) vs placebo during primary PCI for first anterior STEMI
FAILED its primary endpoint: no reduction in infarct size (CK-MB AUC over 72 h)
No improvement in any prespecified imaging, angiographic, ECG, or clinical outcome
Gwaltney C, Shields A, Love E, Ollis S, Stokes J, Mazar I, Arenson E, Aiudi A, Wirth RJ, Houts C. · Orphanet journal of rare diseases (2025)
Results Among the N = 12 white males (M age = 19.5, SD = 7.7) participating in the TAZPOWER trial, overall symptoms were rated as mild (n = 5, 41.7%), moderate (n = 5, 41.7%), severe (n = 1, 8.3%), or very severe (n = 1, 8.3%).
The BTHS-SA may be a useful tool to evaluate treatment benefits in this underserved population.
Einfach gesagt: Herein we evaluate the emerging role of PLSCR3 as a potentially druggable mitochondrial target, supported by recent genetic, biochemical, and in vivo evidence, and discuss translational strategies that may bridge the gap between experimental promise and clinical application.
Patel PS, Pabla NS, Bajwa A. · Seminars in nephrology (2026)
This review synthesizes current mitochondrial-directed approaches for AKI, with a particular emphasis on the mechanistic role of PLSCR3 in maintaining mitochondrial homeostasis and injury responses.
Despite encouraging data, mitochondrial therapies face several translational hurdles, including limited bioavailability, challenges in establishing effective dosing regimens, incomplete mechanistic understanding, and variability in efficacy across different experimental models.
Moreover, concerns regarding cost, accessibility, and long-term safety remain unresolved, contributing to inconsistent outcomes in clinical trials.
Einfach gesagt: While short-term studies indicate that mitoAOXs are generally well tolerated, there is currently limited evidence to support the use of mitoAOXs in the management of glycaemic control and cardiovascular health.
Mason SA, Wadley GD, Keske MA, Parker L. · Diabetes Obes Metab (2022)
Systematic review and meta-analysis of 19 RCTs (n=884) of mitochondrial-targeted antioxidants — Elamipretide, MitoQ and MitoTEMPO — searched through June 2021
Pooled mitoAOXs significantly improved brachial flow-mediated dilation (3 trials; SMD 1.19, 95% CI 0.28-2.16) but with very-low evidence certainty; no significant effect on any glycaemic, cardiovascular or oxidative-stress outcome
Subcutaneous elamipretide specifically increased mild-to-moderate injection-site events; no serious treatment-emergent adverse events across mitoAOXs
Einfach gesagt: For the 6-minute walk test, the least-squares mean difference between elamipretide-treated patients and natural-history controls was 79.7 m (P = 0.0004) at week 64.
Hornby B, Thompson WR, Almuqbil M, Manuel R, Abbruscato A, Carr J, et al. · Orphanet J Rare Dis (2022)
Phase 3 observational, retrospective study comparing 8 TAZPOWER open-label-extension patients with 19 untreated natural-history controls via propensity scoring
Reported significant 6MWT and muscle-strength advantages for elamipretide and increased LV stroke volume
Designed to bolster the open-label efficacy signal because the randomized trial portion was not conclusive